News & Insights
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
View Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
maxon acquires strategic minority stake in Synapticon
View maxon acquires strategic minority stake in Synapticon
Norsk Titanium AS: Agreement on USD 10 million growth funding from Claret Capital Partners to strengthen liquidity and support strategic growth
View Norsk Titanium AS: Agreement on USD 10 million growth funding from Claret Capital Partners to strengthen liquidity and support strategic growth
Investor Day 2025
View Investor Day 2025
Claret Capital Partners Strengthens Team with the Addition of Two Senior Hires
View Claret Capital Partners Strengthens Team with the Addition of Two Senior Hires
Claret Capital Partners supports PRODA’s global expansion with growth facility
View Claret Capital Partners supports PRODA’s global expansion with growth facility